Riziki Kisonga

Riziki Kisonga

Auto-generated profile, based on publicly available information

Riziki Kisonga

National Tuberculosis and Leprosy Programme, Ministry of Health

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AEAndrew Ebers
Andrew Ebers
SSSuzanne Stroup
Suzanne Stroup
SMStellah G. George Mpagama
Stellah G. George Mpagama
RKRiziki Kisonga
Riziki Kisonga
ILIsaack Lekule
Isaack Lekule
SHScott Heysell
Scott Heysell
Therapeutic drug monitoring may improve multidrug-resistant tuberculosis (MDR-TB) treatment outcomes. Levofloxacin demonstrates significant individual pharmacokinetic variability. Thus, we sought to develop and validate a high-performance liquid chromatography (HPLC) method with ultraviolet (UV) detection for levofloxacin in patients on MDR-TB treatment. The HPLC-UV method is based on a solid phase extraction (SPE) and a direct injection into the HPLC system. The limit of quantification was 0.25 μg/mL, and the assay was linear over the concentration range of 0.25—15 μg/mL (y = 0.5668x—0.0603, R2 = 0.9992) for the determination of levofloxacin in plasma. The HPLC-UV methodology achieved excellent accuracy and reproducibility along a clinically meaningful range. The intra-assay RSD% of low, medium, and high quality control samples (QC) were 1.93, 2.44, and 1.90, respectively, while the inter-assay RSD% were 3.74, 5.65, and 3.30, respectively. The mean recovery was 96.84%. This method was then utilized to measure levofloxacin concentrations from patients’ plasma samples from a retrospective cohort of consecutive enrolled subjects treated for MDR-TB at the national TB hospital in Tanzania during 5/3/2013–8/31/2015. Plasma was collected at 2 hours after levofloxacin administration, the time of estimated peak concentration (eCmax) treatment. Forty-one MDR-TB patients had plasma available and 39 had traceable programmatic outcomes. Only 13 (32%) patients had any plasma concentration that reached the lower range of the expected literature derived Cmax with the median eCmax being 5.86 (3.33–9.08 μg/ml). Using Classification and Regression Tree analysis, an eCmax ≥7.55 μg/mL was identified as the threshold which best predicted cure. Analyzing this CART derived threshold on treatment outcome, the time to sputum culture conversion was 38.3 ± 22.7 days vs. 47.8 ± 26.5 days (p = 0.27) and a greater proportion were cured, in 10 out of 15 (66.7%) vs. 6 out of 18 (33.3%) (p = 0.06) respectively. Furthermore, one patient with an eCmax/minimum inhibitory concentration (MIC) of only 1.13 acquired extensively drug resistant (XDR)-TB while undergoing treatment. The individual variability of levofloxacin concentrations in MDR-TB patients from Tanzania supports further study of the application of onsite therapeutic drug monitoring and MIC testing.

1 December 2018 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
MSMargaretha Laurent Sariko
Margaretha Laurent Sariko
AMAthanasia Maro
Athanasia Maro
JGJean Gratz
Jean Gratz
EHEric Houpt
Eric Houpt
RKRiziki Kisonga
Riziki Kisonga
TTTania A. Thomas
Tania A. Thomas
Introduction: There is active interest in leveraging host immune responses as biomarkers of tuberculosis (TB) disease activity. We had previously evaluated an immunodiagnostic test called the antibody in lymphocyte supernatant (ALS) assay. Here, we aimed to evaluate a panel of inflammatory mediators and associate the responses with the ALS results to identify a biosignature to distinguish TB cases from controls. Methodology: In this case–control study, adults with TB were compared to controls who were hospitalized for non-infectious conditions. Blood was collected at baseline and after 4 weeks of TB treatment (from TB cases only). Peripheral blood mononuclear cells were isolated and cultured without antigenic stimulation for 72 hours. Inflammatory mediators were measured using the Multiplex cytokine kit and compared between TB cases and controls; among TB cases, responses were compared over time. ALS and inflammatory mediator results were evaluated using generalized discriminant analysis to identify the optimal biosignature to predict TB. Results: When comparing inflammatory mediators between groups, IL-1ra, IL-1β, and granulocyte macrophage-colony stimulating factor (GM-CSF) were lower in TB cases (P<0.002). Fibroblast growth factor-basic significantly increased from baseline to week-4 (P=0.002). Generalized discriminant analysis yielded a model with IL-2, tumor necrosis factor-alpha, vascular endothelial growth factor, and ALS, providing a sensitivity of 82.2% and specificity of 76.2%. Conclusion: Our results suggest that IL-1ra, IL-1β, and GM-CSF might be used as diagnostic biomarkers to distinguish between TB cases and non-TB cases. We could not identify a group of mediators that outperformed the diagnostic accuracy of the ALS alone.

17 December 2024 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
DPDoreen Pamba
Doreen Pamba
ESErica Sanga
Erica Sanga
KMKillian Mlalama
Killian Mlalama
LMLucas Maganga
Lucas Maganga
CMChacha Mangu
Chacha Mangu
NNNyanda Elias Ntinginya
Nyanda Elias Ntinginya
Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus rifapentine (3HP) TB preventive treatment in January 2024. The 3HP completion rate is generally ≥80%, varying by delivery strategy and programmatic setting. Before the roll-out, a mixed methods study was conducted to assess whether a family approach involving family member support, SMS reminders, and three health education sessions was acceptable and optimized 3HP uptake and completion. This paper describes acceptability of the family approach among people living with HIV (PLHIV), treatment supporters (TS), and community health workers (CHWs). This was a qualitative descriptive study in 12 HIV care and treatment centers across six administrative regions. We purposively sampled 20 PLHIV, 12 CHWs for in-depth interviews, and 23 TS for three focus group discussions held between September and December 2023. The theoretical framework of acceptability guided thematic-content analysis using a framework approach. Participants understood that PLHIV have an increased risk for active TB and that 3HP provides shortened treatment for TB disease prevention. They learned about TB and 3HP through health education sessions, but participation of TS was low due to expensive transportation costs to clinics. Receiving support from a trusted person and SMS were perceived as good adherence reminders. The majority reported mild self-limiting side effects but expressed positive attitudes because of the shortened treatment, TB counseling, satisfaction from helping others, lifestyle and work alignment, and reduced work burden. Some PLHIV had difficulties identifying supportive family members, so they chose close friends or CHWs. The family approach to supporting 3HP adherence is widely accepted by PLHIVs, TS, and CHWs in the context of person-centered care that respects their preferences. We recommend its adoption in programmatic settings as a combined approach, considering changes made during the study. However, further research is warranted to assess its acceptance among other populations eligible for 3HP.

7 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
NMNelly Mwageni
Nelly Mwageni
ASAnne Schoenmakers
Anne Schoenmakers
RWRobin van Wijk
Robin van Wijk
DKDeus V. Kamara
Deus V. Kamara
RKRiziki M. Kisonga
Riziki M. Kisonga
SMStephen Mshana
Stephen Mshana
Background: Skin diseases, including skin-related neglected tropical diseases (NTDs), contribute substantially to the global disease burden, particularly in low- and middle-income countries. Strengthening community health programmes to promote early diagnosis and treatment of skin conditions is essential. This study describes skin diseases identified during community-based integrated skin screening events conducted as part of the PEP4LEP project in three districts in Tanzania. A second objective is to use prevalence data to inform integrated skin health and NTD strategies within Tanzania and in similar contexts beyond. Methodology: A cross-sectional study was conducted within the PEP4LEP implementation research project between December 2019 and March 2024. Community ‘skin camps’ were organised near leprosy index patients – without disclosing their disease status – to screen contacts from the 20 nearest households and administer preventive medication to those eligible. A dermatologist screened participants and provided medical advice, medication (prescriptions) and/or referrals. Demographic data and diagnoses were registered. A subset of participants also completed an additional questionnaire. Paper-based data were entered into REDCap and Microsoft Excel, and analysed in SPSS and Stata using descriptive statistics and Chi-square tests. Results: Of the 4,501 persons screened during 44 community skin camps, 2,527 (56.1%) were diagnosed with one or more skin diseases, of whom 392 (15.5%) had multiple conditions. Among 2,959 recorded diagnoses, 92 distinct skin diseases were identified. The most common conditions were tinea capitis (24.0% of diagnoses), pityriasis versicolor (13.0%), and scabies (7.3%). Five skin NTDs were seen among 280 participants, accounting for 6.2% of all screened individuals and 9.5% of all diagnoses: scabies, leprosy (1.5% of diagnoses), onchocerciasis (0.5%), lymphatic filariasis (0.1%), and chromoblastomycosis (0.03%). Of the 1,841 dermatological patients who completed the additional questionnaire, 28.3% had previously sought medical care, with over half (54.6%) consulting drug-selling shops. Conclusion: Over half of the community members screened in Tanzanian skin camps had at least one skin condition, with skin NTDs accounting for almost 10% of diagnoses. Strengthening integrated, community-based dermatological and NTD control approaches is vital to improve early detection and treatment, particularly in underserved areas.

20 March 2025 in medRxiv
Verified
Preprint
Open access
PDF file
DPDoreen Pamba
Doreen Pamba
ESErica Sanga
Erica Sanga
WWWiston William
Wiston William
HMHappiness Mvungi
Happiness Mvungi
HOHamimu Omary
Hamimu Omary
LMLucas Maganga
Lucas Maganga
Objective: To describe challenges posed by COVID-19 on TB commodity supply, care cascade, active case finding, and responses taken by healthcare workers (HCWs) and community health workers (CHWs) during the first year of the pandemic (March 2020 to February 2021). Design: A qualitative descriptive study involving 25 in-depth interviews and 10 focus group discussions conducted in July 2022. Setting: 37 TB treatment facilities were purposively selected from seven regions due to high TB case notifications in 2019 and their provision of TB and COVID-19 services during the first year of the pandemic (March 2020 to February 2021). Participants: Purposive selection of 58 HCWs and 55 CHWs who provided TB services in the first year of the COVID-19 pandemic. Results: HCWs reported unusual stockouts and delayed receipt of GeneXpert cartridges and sputum containers. TB services faced a decline in client attendance, as clients were hesitant to undergo TB screening, sputum sample collection, and contact tracing due to fear of contracting or being diagnosed with COVID-19 and subsequently being quarantined. To mitigate these challenges, HCWs used alternative containers for sputum sample collection, optimized GeneXpert cartridges use by prioritizing GeneXpert testing for TB risk groups, and diagnosed TB by microscopy, chest X-ray, and sputum pooling method. Moreover, they extended drug refill schedules to minimize the risk of contracting COVID-19 in clinics. CHWs used mobile communication for client tracing and focused household visits on TB risk groups. Conclusion: COVID-19 disrupted TB commodity availability and TB treatment-seeking behavior. Adaptations like multi-month drug refills and optimized GeneXpert use, supported the TB healthcare system’s resilience. While these adaptations offer valuable insights for strengthening TB service delivery, their effectiveness and sustainability require further evaluation. Thus, prospective studies could clarify their long-term impact. National Tuberculosis Programs could consider adapting these practices post-pandemic, with appropriate modifications to suit different contexts. STRENGTHS AND LIMITATIONS OF THIS STUDY: The study provides insights into healthcare providers’ TB management experiences during the first year of COVID-19. Purposive sampling provided insights into TB service delivery across diverse healthcare cadres and facilities in high-COVID-19 regions. Triangulation of data collection methods and researchers enhanced credibility by ensuring data consistency and reducing potential bias. Retrospective data collection may have introduced recall bias but mitigated through data triangulation. Focusing on high-COVID-19 regions may limit the transferability of findings to less COVID-19 affected areas with different TB service challenges.

5 April 2024 in medRxiv
Verified
Preprint
Open access
PDF file
DPDoreen Pamba
Doreen Pamba
ESErica Sanga
Erica Sanga
KMKillian Mlalama
Killian Mlalama
LMLucas Maganga
Lucas Maganga
CMChacha Mangu
Chacha Mangu
NNNyanda Elias Ntinginya
Nyanda Elias Ntinginya
Introduction Tanzania rolled-out a 12-dose, weekly regimen of isoniazid plus rifapentine (3HP) TB preventive treatment in January, 2024. Although 3HP completion rate is generally ≥ 80%, variations exist depending on type of delivery strategy and programmatic setting. Prior to the roll-out, a mixed methods study was conducted to assess whether a family approach involving family member support, SMS reminders and three health education sessions, was acceptable and optimized 3HP uptake and completion. This paper describes acceptability of the family approach among people living with HIV (PLHIV), treatment supporters (TS) and community health workers (CHWs). Methods This was a qualitative descriptive study in 12 HIV care and treatment centers across six administrative regions. We purposively sampled 20 PLHIV, 12 CHWs for in-depth interviews and 23 TS for three focus group discussions held between September to December, 2023. The theoretical framework of acceptability guided thematic-content analysis using a framework approach. Results Participants understood that PLHIV have high risk for active TB and that 3HP provides shortened treatment for TB disease prevention. They reported gaining TB and 3HP knowledge from health education sessions. However, participation of TS in health education sessions was low and many reported expensive transportation costs to clinics. Receiving support from someone close and SMS were perceived as good adherence reminders. The majority reported mild self-limiting side effects but expressed positive attitudes because of the shortened treatment, TB counselling, satisfaction from helping others, alignment with lifestyle and work responsibilities and reduced work burden. Some PLHIV reported difficulties in identifying family members for support thus, chose other close friends or CHWs. Conclusions Delivery of 3HP with support from family members and SMS reminders is widely accepted by CHWs, PLHIVs and TS. Restricting support from only family members was unacceptable and attendance of all three health education sessions by TS may not be feasible.